|Bid||32.83 x 800|
|Ask||33.55 x 900|
|Day's Range||30.71 - 33.54|
|52 Week Range||2.94 - 60.00|
|Beta (5Y Monthly)||7.46|
|PE Ratio (TTM)||N/A|
|Earnings Date||Nov 10, 2020|
|Forward Dividend & Yield||N/A (N/A)|
|1y Target Est||65.67|
SEATTLE, WA / ACCESSWIRE / January 11, 2021 / Aptevo Therapeutics Inc. ("Aptevo" or the "Company") (NASDAQ:APVO), a clinical-stage biotechnology company focused on developing novel immuno-oncology therapeutics based on its proprietary ADAPTIR™ and ADAPTIR-FLEX™ platform technologies, today provided an update on its ongoing APVO436 phase 1 clinical trial.
Aptevo Therapeutics Inc. (APVO) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank 2 (Buy).
PHILADELPHIA, PA / ACCESSWIRE / December 19, 2020 / Kaskela Law LLC announces that it is investigating Aptevo Therapeutics Inc.